Initial treatment for chronic hepatitis C

Article Type
Changed
Tue, 10/30/2018 - 12:12
Display Headline
Initial treatment for chronic hepatitis C
Current therapies and their optimal dosing and duration
Article PDF
Author and Disclosure Information

Keyur Patel, MD
Duke Clinical Research Institute and the Division of Gastroenterology, Duke University Medical Center, Durham, NC

John G. McHutchison, MD
Duke Clinical Research Institute and the Division of Gastroenterology, Duke University Medical Center, Durham, NC

Correspondence: John G. McHutchison, MD, Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P.O. Box 17969, Durham, NC 27715; e-mail:
mchut001@mc.duke.edu

Dr. Patel reported that he has no commercial affiliations or interests that pose a potential conflict of interest with this article.

Dr. McHutchison reported that he has received grant or research support from and is on the speakers’ bureaus of the Schering-Plough and Roche corporations, and that he serves as a consultant to the Schering-Plough corporation.

Publications
Page Number
S8-S12
Author and Disclosure Information

Keyur Patel, MD
Duke Clinical Research Institute and the Division of Gastroenterology, Duke University Medical Center, Durham, NC

John G. McHutchison, MD
Duke Clinical Research Institute and the Division of Gastroenterology, Duke University Medical Center, Durham, NC

Correspondence: John G. McHutchison, MD, Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P.O. Box 17969, Durham, NC 27715; e-mail:
mchut001@mc.duke.edu

Dr. Patel reported that he has no commercial affiliations or interests that pose a potential conflict of interest with this article.

Dr. McHutchison reported that he has received grant or research support from and is on the speakers’ bureaus of the Schering-Plough and Roche corporations, and that he serves as a consultant to the Schering-Plough corporation.

Author and Disclosure Information

Keyur Patel, MD
Duke Clinical Research Institute and the Division of Gastroenterology, Duke University Medical Center, Durham, NC

John G. McHutchison, MD
Duke Clinical Research Institute and the Division of Gastroenterology, Duke University Medical Center, Durham, NC

Correspondence: John G. McHutchison, MD, Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P.O. Box 17969, Durham, NC 27715; e-mail:
mchut001@mc.duke.edu

Dr. Patel reported that he has no commercial affiliations or interests that pose a potential conflict of interest with this article.

Dr. McHutchison reported that he has received grant or research support from and is on the speakers’ bureaus of the Schering-Plough and Roche corporations, and that he serves as a consultant to the Schering-Plough corporation.

Article PDF
Article PDF
Current therapies and their optimal dosing and duration
Current therapies and their optimal dosing and duration
Page Number
S8-S12
Page Number
S8-S12
Publications
Publications
Article Type
Display Headline
Initial treatment for chronic hepatitis C
Display Headline
Initial treatment for chronic hepatitis C
Citation Override
Cleveland Clinic Journal of Medicine 2004 May;71(suppl 3):S8-S12
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Treatment strategies for hepatitis C: Making the best of limited options

Article Type
Changed
Tue, 02/12/2019 - 11:49
Display Headline
Treatment strategies for hepatitis C: Making the best of limited options
Article PDF
Author and Disclosure Information

John G. McHutchison, MD
Director, Liver Transplantation Program; Division of Gastroenterology/Hepatology, Scripps Clinic and Research Foundation; La Jolla, Calif

Zobair Younossi, MD, MPH
Section of Hepatology, Department of Gastroenterology, Cleveland Clinic

Address: Zobair Younossi, MD, Department of Gastroenterology, S40, Cleveland Clinic, 9500
Euclid Avenue, Cleveland, OH 44195

Dr. McHutchison receives grant or research support from the Schering-Plough, Amgen, Roche, and Gilead companies, has served as a consultant for Schering-Plough and Roche, and has served on speakers' bureaus for Schering-Plough, Roche, and Amgen.

Dr. Younossi receives research support from Schering-Plough, Roche, and Interferon Sciences.

Issue
Cleveland Clinic Journal of Medicine - 67(7)
Publications
Topics
Page Number
476-480
Sections
Author and Disclosure Information

John G. McHutchison, MD
Director, Liver Transplantation Program; Division of Gastroenterology/Hepatology, Scripps Clinic and Research Foundation; La Jolla, Calif

Zobair Younossi, MD, MPH
Section of Hepatology, Department of Gastroenterology, Cleveland Clinic

Address: Zobair Younossi, MD, Department of Gastroenterology, S40, Cleveland Clinic, 9500
Euclid Avenue, Cleveland, OH 44195

Dr. McHutchison receives grant or research support from the Schering-Plough, Amgen, Roche, and Gilead companies, has served as a consultant for Schering-Plough and Roche, and has served on speakers' bureaus for Schering-Plough, Roche, and Amgen.

Dr. Younossi receives research support from Schering-Plough, Roche, and Interferon Sciences.

Author and Disclosure Information

John G. McHutchison, MD
Director, Liver Transplantation Program; Division of Gastroenterology/Hepatology, Scripps Clinic and Research Foundation; La Jolla, Calif

Zobair Younossi, MD, MPH
Section of Hepatology, Department of Gastroenterology, Cleveland Clinic

Address: Zobair Younossi, MD, Department of Gastroenterology, S40, Cleveland Clinic, 9500
Euclid Avenue, Cleveland, OH 44195

Dr. McHutchison receives grant or research support from the Schering-Plough, Amgen, Roche, and Gilead companies, has served as a consultant for Schering-Plough and Roche, and has served on speakers' bureaus for Schering-Plough, Roche, and Amgen.

Dr. Younossi receives research support from Schering-Plough, Roche, and Interferon Sciences.

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 67(7)
Issue
Cleveland Clinic Journal of Medicine - 67(7)
Page Number
476-480
Page Number
476-480
Publications
Publications
Topics
Article Type
Display Headline
Treatment strategies for hepatitis C: Making the best of limited options
Display Headline
Treatment strategies for hepatitis C: Making the best of limited options
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media